MARKET

ABIO

ABIO

Arca Biopharma Inc
NASDAQ
3.630
-0.020
-0.55%
After Hours: 3.680 +0.05 +1.38% 16:33 04/24 EDT
OPEN
3.640
PREV CLOSE
3.650
HIGH
3.734
LOW
3.600
VOLUME
97.71K
TURNOVER
0
52 WEEK HIGH
3.880
52 WEEK LOW
1.560
MARKET CAP
52.64M
P/E (TTM)
-9.8002
1D
5D
1M
3M
1Y
5Y
Arca Biopharma Increases Executive Retention Bonuses
TipRanks · 1d ago
Weekly Report: what happened at ABIO last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at ABIO last week (0408-0412)?
Weekly Report · 04/15 12:12
Weekly Report: what happened at ABIO last week (0401-0405)?
Weekly Report · 04/08 12:18
ARCA biopharma 13D Filing Shows Adage Capital Management, L.P. Reported A 8.28% Stake In The Co As Of April 3, 2024
Benzinga · 04/05 20:17
ADAGE CAPITAL MANAGEMENT, L.P. REPORTS 8.28% STAKE IN ARCA BIOPHARMA AS OF APRIL 3- SEC FILING
Reuters · 04/05 20:16
ARCA Biopharma stock drops on CEO departure
ARCA Biopharma shares down about 7% premarket after company and CEO Michael Bristow mutually agreed to conclude Bristow’s employment and service as a director. The Board appointed Thomas Keuer to serve as ARCA's President and principal executive officer. ARCA biopharma stock drops on CEO departure.
Seeking Alpha · 04/05 13:06
Altice USA, Genfit, Brooge Energy among premarket losers' pack
On the Move: Altice USA, Genfit, Brooge Energy among premarket losers' pack. HWH International, ARCA biopharma, ZCMD, HWH among the biggest morning stock movers. ATUS, GNFT, BROG and HWH are among the morning's biggest losers.
Seeking Alpha · 04/05 12:29
More
About ABIO
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.

Webull offers Arca Biopharma Inc stock information, including NASDAQ: ABIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABIO stock methods without spending real money on the virtual paper trading platform.